Bosniak classification of cystic renal masses (2019)
The 2019 revision of the Bosniak classification, class by class — the defining imaging features, the reported malignancy risk, and what each class means for management.
Need the whole report too? Type a few findings and get it written ↓
Summary
| Class | Malignancy risk | Management |
|---|---|---|
| Bosniak I | ~0% (benign) | No follow-up required. |
| Bosniak II | ~0% (benign) | No follow-up required. |
| Bosniak IIF | ~6% | Follow-up imaging. CT or MRI at 6 months, 12 months, then annually for a total of 5 years if stable. |
| Bosniak III | ~55% | Urology referral. Surgical or ablative management, or surveillance in selected patients. |
| Bosniak IV | ~90% | Treat as renal cell carcinoma. Urology referral. |
A sample dictation is ready below. Press generate, or type your own findings and end with “otherwise normal” to have the rest written out. No signup.
100 free reports over 14 days. No card, nothing to install.
Start your free trial →Please leave out patient identifiers. Text is de-identified before the AI sees it and is not stored. Demo output is not for clinical use.
Class by class
Bosniak I
Defining features:
- Well-defined, thin (≤2 mm) smooth wall
- Homogeneous simple fluid (−9 to 20 HU on CT)
- No septa or calcification
- Wall may enhance
Bosniak II
Defining features:
- Few (1-3) thin (≤2 mm) septa, may enhance
- Calcification of any type
- Homogeneous hyperattenuating (≥70 HU) mass at noncontrast CT
- Homogeneous nonenhancing mass >20 HU at renal mass protocol CT
Bosniak IIF
Defining features:
- Many (≥4) thin (≤2 mm) enhancing septa
- Smooth minimally thickened (3 mm) enhancing wall or septa
- MRI only: cystic mass heterogeneously hyperintense at unenhanced fat-saturated T1-weighted imaging
Bosniak III
Defining features:
- One or more thick (≥4 mm) enhancing wall or septa
- One or more enhancing irregular walls or septa (≤3 mm obtuse-margined convex protrusion[s])
Bosniak IV
Defining features:
- One or more enhancing nodule — ≥4 mm with obtuse margins, or any size with acute margins
Using the 2019 revision
- The 2019 revision applies only to cystic renal masses imaged with CT or MRI at renal mass protocol. It is not validated for ultrasound or for masses that are predominantly solid.
- Enhancement may be measured (≥20 HU at CT; ≥15% signal increase at MRI) or perceived qualitatively; thin walls and septa are usually only perceived. Pseudoenhancement is a known pitfall in small intrarenal cysts on CT.
- Version matters: 2019 reclassified several categories relative to the 2005 version and narrowed III considerably. State the version in the report.
Related
Frequently asked questions
Which Bosniak classes need follow-up or treatment?
Bosniak I and II cysts are benign (about 0% malignancy risk) and need no follow-up. Bosniak IIF (about 6% risk) gets surveillance imaging — CT or MRI at 6 months, 12 months, then annually for a total of five years if stable. Bosniak III (about 55% risk) goes to urology for surgical or ablative management or surveillance in selected patients. Bosniak IV (about 90% risk) is treated as renal cell carcinoma.
What imaging does the Bosniak 2019 classification require?
The 2019 revision applies only to cystic renal masses imaged with CT or MRI at renal mass protocol — it is not validated for ultrasound or for predominantly solid masses. Enhancement may be measured (an increase of 20 HU or more at CT, or 15% or more signal increase at MRI) or perceived qualitatively. Pseudoenhancement in small intrarenal cysts on CT is a recognized pitfall.
Why should a report state the Bosniak version used?
The 2019 revision reclassified several categories relative to the 2005 version and considerably narrowed class III, so the same lesion can carry different classes — and different management — under the two versions. Stating 'Bosniak IIF (2019 version)' makes the report unambiguous for the urologist and for later comparison. The 2019 system also added quantitative definitions, such as thin septa at 2 mm or less and thick at 4 mm or more.
MyRadAgent drafts the full report - and applies this guideline automatically, with the category and follow-up in the impression. Free trial runs in the browser: 100 reports over 14 days, no card, no IT ticket.
Try it on a report → or try it here first — no signup ↑BI-RADS, TI-RADS, LI-RADS, PI-RADS, O-RADS, Lung-RADS, CAD-RADS, NI-RADS and ACR are registered trademarks of the American College of Radiology. They are used here only to identify the published systems these tools implement; MyRadAgent is not affiliated with, sponsored by or endorsed by the ACR.